Life Sciences Archive » August, 2019

Life Sciences - August, 2019

319 articles

• Ohio AG Asks 6th Circ. To Halt Upcoming Opioid Bellwether
• Key Health Care And Pharma Policy Debates To Track This Fall
• Eye Device Maker Can't Sue Ex-Partner's Customers Over IP
• Scientists Ask Justices To Overturn $10.5M Fraud Conviction
• Pet Med Cos. Ask 9th Circ. To Revive Merger Challenge
• Ex-Pharmacy Owner Charged In $5M Fraud Scheme
• Argos Says It's Reached Deal To Get Ch. 11 Back On Track
• Key Questions The Oklahoma Opioid Verdict Didn't Answer
• Target Defeats Suit Over 'Worthless' Biotin Supplements
• Ky. Gov. Wins Fight Over Outside Attys In Opioid Suits
• Rx Info Site Fights To Get Off Pharma Groups' Web Blacklists
• Novartis Whistleblower Attys Slam 'Unjust' $1.4M Fee Award
• Deals Rumor Mill: Apcoa, Blued, Smiths Group
• Drugmaker Fine Shows SEC's Renewed Disclosure Focus
• New Best Practices Under E-Discovery Spoliation Rule
• A District Court Split On Hatch-Waxman Venue Determinations
• Allergan To Pay $5M To Exit Ohio Opioid Bellwethers
• Blood Glucose Meter Row Must Be Arbitrated, Fla. Court Hears
• J&J Aims To Cut Calif. Mesh Marketing Trial Short
• Judge Limits Opioid MDL Experts On Compliance, Marketing
• Amgen Cholesterol Drug Patents Nixed, Undoing Jury Verdict
• Gov't Must Restart Medicare Payments To True Health: Judge
• Fed. Circ. Backs Win For Illumina On Scripps Chemical Patent
• Fed. Circ. OKs Order Blocking Generic Of Allergan Eye Drug
• Split Fed. Circ. Backs PTAB Order Junking IPRs On Remand
• Insys Ch. 11 Case Gets Consumer Privacy Watchdog
• Sony To Sell $754M Olympus Stake Following Activist's Calls
• P&G Cancer Trial Win Withstands Fight Over Barred EBay Talc
• How Law Firms Can Create Content Decision Makers Will Read
• Expecting A Pizza Delivered By Drone? It May Take A While
• 4 NY Cases Forge Post-Cyan Securities Litigation Landscape
• White & Case-Led DIC Inks €985M Deal For BASF Pigment Unit
• Okla.'s $572M Win In J&J Opioid Fight On Shaky Ground
• 9th Circ. Wary Of Intervening In Idaho Hemp Seizure Case
• J&J Unit Gets Breast Implants Defect Suits Tossed
• PTAB Grants Narcan IP Review, Rejects Redundant Petitions
• Attys Behind $1B Syphilis Study Suit Beat Sanctions, For Now
• Freeborn Nabs Ex-Katten Pharma Duo For Chicago IP Practice
• Patients Claim Allergan Covered Up Risks Of Breast Implants
• Ex-LeClairRyan Attys Find Homes In DC And Va.
• Ex-Zimmer Exec Fights To Keep Discharge Claim Alive
• Litigation, Regulation Heating Up For E-Cig Manufacturers
• Chemical Plant Emissions Caused Cancer, Ill. Residents Say
• NJ AG Backs J&J Bid To Toss Shareholder Arbitration Suit
• Fed. Circ. Invalidates 5 Of Mallinckrodt's Inomax Patents
• Docs, Med Practice To Pony Up $1.1M To End Kickback Claims
• Wis. Appeals Court Affirms Colgate's Win In Talc Suit
• Prothena Settles Stock-Drop Suit For $15.75M
• Former Obama Official Stumps For NAFTA 2.0 Passage
• When Shareholders Can Bring Direct Claims In Cayman Court
• 4 Key Takeaways As Historic Opioid Ruling Wallops J&J
• Bayer Denied Fees After $155M Hemophilia Drug IP Verdict
• Chancery Says It Can't Enforce NuVasive Noncompete In Del.
• Asbestos Rarely Causes Cancer In Women, J&J Talc Jury Told
• FDA Decries Erectile Dysfunction Drug Promo In New Warning
• Tufts Grad Student Hits School, Staff With Retaliation Suit
• Religious Parents Can't Get Freeze On NY Vaccination Law
• PE-Backed Shoe Retailer Cole Haan Gears Up For IPO
• 5 Firms Vie For Lead In Latest Teva Investor Suit
• Pa. Justices Urged To OK Venue In $12.5M J&J Mesh Litigation
• Loestrin Buyers Say Splitting Trial In 3 Would Cause Chaos
• Akorn's $30M Investor Deal Over Failed Merger Gets 1st OK
• FTC Fights E-Prescription Co. Bid To Nix Monopoly Case
• Okla. Judge Rules J&J Caused Opioid Crisis, Owes $572M
• US Trustee Skeptical As Aegerion Creditors OK Ch. 11 Plan
• Latham, Fenwick Steer Up To $400M Deal For Biotech Modis
• 5 Firms Shape Amgen's $13.4B Celgene Drug Buy
• Juul Trims But Can't Escape E-Cigarette Labeling Suit
• Ill. Officials Report 1st Possible Death Linked To Vaping
• CVS Says Sentry's Heel-Dragging On Doc Production 'Tactical'
• PTAB Puts U. Of Minn. Reviews On Ice For High Court Appeal
• J&J, Okla. Face Moment Of Truth In Milestone Opioid Trial
• Takeda Unit Can't Undo $155M Loss In Bayer IP Row
• 2 Cannabis Bills Would Benefit Banks, Businesses And Gov't
• Adocia's $1.8B Claim Against Eli Lilly Dies In Arbitration
• Allergan Beats Patient Suits Over Implant Warranty Program
• FTC Cybersecurity Cases Highlight Benefits, Risks Of Settling
• Awaiting Answers On A Post-Bristol-Myers Class Question
• Crafting Motions To Seal After 3rd Circ. Avandia Decision
• SEC Breaks Yearslong Silence On Selective Disclosures
• Mylan Partially Beats Amgen Neulasta Biosimilar Claims
• True Health Says Medicare Withholding Violates Ch. 11 Stay
• Aegerion Pharma's Ex-CEO Objects To Ch. 11 Plan
• 7th Circ. Vacates Illustrator's $3.6M Copyright Damages Award
• ViSalus Can't Decertify Class In $925M Robocall Case
• DOJ Hammers 'Unprecedented' Rejection Of FCA Dismissal
• Teva Beats Nestle Unit's Suit Over Rosacea Cream Patents
• King & Spalding Adds Health Care Pro From Hooper Lundy
• Insys Ch. 11 Sales For Two Drug Lines Approved In Del.
• Deal Reached In Anixa Repriced-Stock Suit In Chancery
• New Clarity On Expert Testimony In Pa. State Courts
• Clinical Stage Therapeutics Group Raises $53M
• Chiasma Investors Want Bond From 'Frivolous' Deal Objectors
• Chinook Raises $65M Series A For Kidney Disease Treatments
• Gilead Challenges HHS' HIV-Prevention Patents
• Pa. Justices Snub Appeal Of $2M J&J Pelvic Mesh Award
• Ohio High Court Revives Wrongful Death Suit Against Amazon
• ADHD Drug Indirect Purchasers Lose Antitrust Class Cert. Bid
• Crypto Addresses Blacklisted In OFAC Fentanyl Sanctions
• Commerce Opens Probe Into Imported Thermoplastic Sheet
• 32 New Lawsuits Filed Against Sterigenics In Ill. State Court
• Dow Corning Settles 22-Year Interest Fight With $172M Payout
• PTAB Will Review 2 Guardant Diagnostic Patents
• Pharmacy Retailers Fight Glenmark's Bid To Exit Zetia MDL
• DOJ Seems Gun-Shy With New FCA Penalty Firepower
• Fed. Circ. Says PTAB Didn't Violate Arthrex's Rights
• Calif. Likely To Have More CEQA 'Projects' Following Ruling
• Feds Look To DC Circ. To Revive Drug Pricing Rule
• CBD Producer Says Ex-VP Lied About Having An Equity Stake
• Biotech Cos. Say Cancer-Killing Cell IP Fight Can Be Litigated
• Conglomerate 3M Seeks $3.3B Bond Sale To Fund Acelity Buy
• 7th Circ. Revives Suit Over PetSmart's 'Prescription' Cat Food
• Litigation Finance Can And Should Protect Its Reputation
• Cancer-Focused Biotech Lands $79.5M Series B Round
• Ex-Medline Chemist's ADA Suit Comes Up Short, Judge Finds
• Considering Disclosure Risks In Sensitive Product Recalls
• Insys Creditors Want More Guarantees In Severance Plan
• Calif. Surgeon Testifies J&J Mesh Has Low Complication Rate
• 9th Circ. Shuts Door On Medtronic Obesity Bias Suit
• NY Parents Can't Keep Vaccine Exemption For Disabled Kids
• FDA Hit With Suit Over E-Cigarette Regulation
• ViSalus, Consumers Brawl Over Decert. Bid In Robocall Suit
• Zimmer Urges ITC To Block Rival's Bone Cements From US
• Drugmaker Pays $200K To End SEC Fight Over Study Leaks
• San Diego Pot Zoning Rules Need Enviro Review, Justices Say
• Jones Day Snags Ex-MoFo Patent Litigation Partner In LA
• 'Shadowy' Co. Can't Ignore Eli Lilly's $20M High Court Appeal
• 8th Circ. Upholds Monsanto's $21.5M Roundup Label Deal
• Fed. Circ.'s Arduous Legal Landscape For Diagnostic Patents
• Endo, Perrigo Strike Deal In Nasal Spray Patent Suit
• Pfizer Says It Shouldn't Be Included In EpiPen Class Cert. Bid
• FDA Accused Of Dodging Food Safety Mandate
• Endo Pays $10M To Exit Opioid MDL Bellwethers
• 5 Firms Steer Elanco's $7.6B Bayer Animal Biz Buy
• California Rests Case In Ethicon Mesh False-Marketing Trial
• Nicotine-Addicted Teen Drops Juul False Ad Suit
• Lead Attys Approved For Opioid MDL 'Negotiation Class'
• 4 Drug Cos. Strike $1.5M Deal In Namenda Pay-For-Delay Suit
• IQVIA Says 'Duplicative' Antitrust Claims Belong In NJ
• J&J Talc Educator Never Saw Asbestos Reports, Jury Hears
• 4 Life Science Cos. Lead 5 IPO Filings Totaling $476M
• Walgreens Not Liable To Crash Victims After Drug Mix-up
• Fresenius Seeks $46M In Del. For Broken Merger Legal Fees
• Class Settlements And The Risks Of Viral Media Attention
• Crisis Messaging To Protect Law Firm Brand And Bottom Line
• Weil's Bid To Intervene In Insys Conflict Faces Opposition
• Chemo MDL Patients Shred Sanofi Bid To Delay Bellwether
• Fed. Circ. Backs Sanofi Cancer Drug IP Win, Delaying Generic
• Fed. Circ. Backs PTAB's Gutting Of Enzo DNA Test Patent
• LabCorp Can't Escape All Claims In Suit Over Lab Test Billing
• Toxic Supplement Suit Lacks Proof, Vitamin Shoppe Says
• New Compliance Steps For Filing Drug Co. Settlements
• Glenmark Wants Out Of Pharmacies' Pay-For-Delay Lawsuits
• SC AG Hits 3 Opioid Distributors With Suit Over Crisis
• Sterigenics Emissions Suits Kicked Back To Ill. State Court
• True Health Creditors Say DIP Terms Guarantee Default
• Breast Implant Co. CEO To Pay $160K Over Offering Omission
• 4th NY Doc Charged With Taking Insys Kickbacks Cops Plea
• Judge Says Bid To Nix Valeant Stock-Drop Suit Unnecessary
• Drugmakers Can't Ax MDL's 'Overarching Conspiracy' Claims
• Will FDA Cigarette Warnings Pass Constitutional Scrutiny?
• Actavis Dooms Exforge Buyers' Pay-For-Delay Claims
• With 'New Rule,' Fed. Circ. Upholds Weight Loss Pill Patent
• PTAB To Review Tissue Graft Patent After LifeNet $35M Win
• $925M Robocall Class Says Decert. Bid Is 'Manifestly Unfair'
• J&J Talc Wasn't Dusty Enough To Cause Cancer, Jury Told
• NY AG Issues 33 Subpoenas In Purdue Pharma Opioid MDL
• What You Should Know About Courtroom Closures
• Deals Rumor Mill: ChemChina, SIX Swiss Exchange, Revlon
• WTO Dispute Roundup: Solar, Sugar Cases Plow Ahead
• Cohen Milstein Seeks Lead In Zimmer Biomet PE Cashout Suit
• True Health Creditors Ask To Join Medicare Withholding Suit
• The 50-Year Evolution Of US Cigarette Warnings
• FDA Unveils New Graphic Warnings For Cigarette Packs
• Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay
• Lawmakers Press For Pricing Info From Teva, Mylan, Heritage
• Online Pharmacy Co. Hits Industry Orgs With Antitrust Suit
• DOJ Takes Another Shot At Suboxone Film Fraud Case
• Zimmer Says Ex-Exec Can't Relitigate Discharge Claim
• Quinn Emanuel Nabs Shearman Arbitration Partner In NYC
• Pharma Co. Mallinckrodt Gets Firing Suit Kicked To Arbitration
• Fed. Circ. Backs Sanofi In Prostate Cancer Drug Patent Fight
• Deals Rumor Mill: KKR, OCBC Bank, ExxonMobil
• Customers Win Class Cert. In TCPA Suit Against McKesson
• Invisalign Investors Fight Bid To Ax Suit Over Expiring Patents
• Maker Of Defibrillator Vest To Face Trial In Suit Over Death
• Pharma Wholesalers Strike $7.5M Deal In Drivers' OT Suit
• The Outlook On Drug Pricing And Surprise Billing In Congress
• Protecting Medical Method Patents Via Indirect Infringement
• Eli Lilly Unit Sues Alzheimer's Institute For IP 'Conspiracy'
• J&J Baby Powder 'Never' Had Asbestos, NJ Jury Told
• Risperdal Patient Slams J&J's Bid To Dodge Damages Trial
• Covington Reps Biopharma Co. Landos' $60M Funding Round
• Sanofi, Novo, Lilly Look To Ditch Minn. AG's Insulin Suit
• Mesh Maker Must Face Most Claims In Bellwether Suit
• UK Probes Kohlberg's Purchases Of Packaging Suppliers
• Blue Cross Looks To Duck Heart Monitor Co.'s Revived Suit
• Why I Became A Lawyer: A Seaweed Scientist's Odyssey
• DOJ Enforcement Insights From Poultry Price-Fixing Case
• Patent Opportunities In FDA Bispecific Antibody Guidance
• Ex-MLB Player Gets Time Served For Insider Trading
• Investors' Impax Drug Price-Fixing Suit Fails Again
• How To Counter Jury Reliance On Plaintiff's Damages Ask
• Key Expert In Ethicon Mesh Trial Grilled Over Marketing Study
• Mesh Maker Can't Trim MDL Bellwether Alleging It Hid Dangers
• J&J Pounces On Asbestos Testing Method At NJ Talc Trial
• Glancy Asks To Lead Med. Device Co. Stock-Drop Suit
• Feds Say Insys Needs Consent To Sell Gov't Deals In Ch. 11
• Norton Rose Nabs Perkins Coie Health Care Enforcement Atty
• Shook Hardy Opens Boston Office, Adds 4 Philly Attys
• Akorn Seeks OK On $30M Deal Over Failed Merger
• Pharmas Seek Separate Fraud, Antitrust Trials In Loestrin MDL
• Fla. Nerve Repair Co. Hit With Investor Suit Over Stock Drop
• 3 Best Practices For Patent Claims Against Secret Methods
• Amgen Patents Beat Sandoz Validity Check In Biosimilar Fight
• J&J Disputes Asbestos-Mesothelioma Link At NJ Talc Trial
• Humana Says Acthar's Meteoric Price Hike Cost It $700M
• Fed. Circ. Backs Wins For Eli Lilly Over Cancer Drug Patent
• CBD Co. Lied About Access To Tribal Land, SEC Says
• Zetia Buyers' Pay-For-Delay Lawsuits Will Press On
• Court OKs $65.8M Deal In Cephalon Pay-For-Delay Suit
• Providers Take Another Stab At Syringe Antitrust Suit
• Sens. Slam Novartis-Owned Co. For Hiding Bogus Data
• Fed. Circ. Nixes Labrador Retriever Genetic Test Patent
• Athenex Ruling Helps Clarify FDA Drug Compounding Policy
• Using Global Dossier To Simplify USPTO Disclosure Duty
• Ex-Novartis Exec's Attys Get $1.4M Fees In Whistleblower Suit
• 3rd Circ. Decision Limits Liability Of Board Observers
• Insys Plans $29M CBD And Naloxone Sale In Ch. 11
• What We Know About Opioid MDL Settlement Talks
• Novartis Attys Get Reduced Fees Over Whistleblower's Antics
• Investment Pro Denies Role In $6M Illumina Insider Tips Scam
• 'My Grandmother Could Have Filed This,' Valeant Judge Says
• Med Device Co. Settles FCA Trade Violation Claims For $3.3M
• Gov't Fights Insys Founder's Bid To Delay Sentencing
• Israeli Medical Device Co. Raises $70M In IPO
• 5th Amendment Strategy For Parallel Civil, Criminal Litigation
• What OIG Self-Disclosure Guidance Means For HHS Grantees
• Hospitals Want Claim In Insys Ch. 11 That Could Hit $102B
• Orrick, Goodwin Steer Bayer's $240M BlueRock Buy
• Aetna Faces Suit Over Lumbar Disc Surgery Coverage
• Clients Benefit From Law Firm Expense Growth
• Siemens Set To Buy Cadwalader-Led Robotics Biz For $1.1B
• Top Ethicon Doctor Defends Mesh Warnings In Calif. Trial
• J&J Targets Scientist's Talc Studies In Cancer Trial
• Aceto, 3 Execs Escape Stock-Drop Suit For Now
• Cynosure Gets Quick Win In Suit Over Fat-Reduction System
• Boston Scientific Wins FTC Clearance For £3.3B BTG Deal
• Fed. Circ. Urged To Reconsider Enzo DNA Patent Case
• Fed. Circ. Won't Stay Vimovo Case Despite Looming Generic
• Fired Alcon Sales Rep Says Bias 'Permeated The Workforce'
• Pa. Appeals Court Hints At Backing $70M Risperdal Verdict
• IRS Slams Pot Shop's Bid To Restore $600K Write-Off
• Changing Ethics Rules Is Key To Law Firm Innovation
• 5 Insurance Coverage Questions Raised By Opioid Litigation
• Feds Narrow Insider Trading Case Against Rep. Chris Collins
• Kirkland, Skadden Steer Permira's $2.4B Cambrex Buy
• J&J Fixes On Remark Calling Asbestos In Talc 'Urban Legend'
• Agriculture Startup Raises $89M In Series C Funding Round
• Fed. Circ. Backs ITC's Infringement Ruling On E. Coli Patent
• Novartis Hid Bogus Data, May Face Penalties, FDA Says
• Womble Bond Adds Bracewell IP Pro In Houston
• Allergan Can't Escape Generic Drug Price-Fixing Suit
• DePuy Gets $8.2 Million Patent Judgment Slashed In Half
• Home Depot Hit With Suit Over Roundup Sales
• National Coordinating Counsel: Key To Virtual Mass Tort Team
• Mylan Blasts '11th Hour' Discovery Push In EpiPen Row
• Considering The Current And Future Legality Of CBD
• McKesson Tries To Nix Derivative Suit Over Drug Price-Fixing
• From Roundup To Oatmeal: New Trends In Glyphosate Suits
• Unprecedented Agency Divergence On Antitrust Enforcement
• Opioid MDL Judge Signals Support For 'Negotiation Class'
• Timetable For Opioid MDL Trial 'Entirely Untenable': Drug Cos.
• Ex-FDA Czar Says J&J Mesh Paperwork Left Out Risk Info
• J&J Challenges Scientist's Baby Powder Asbestos Findings
• Discovery Rules Adopted In J&J Talc Supplier Ch. 11 Case
• Smith & Nephew Get Partial Win In Hip Implant MDL
• Hooper Lundy Nabs Jones Day Partner To Spearhead IP Group
• Cooperation Lets Pharma IT Pro Duck Jail In $94M Theft Case
• Imprimis Fails To Nix Jury Award In Allergan False Ad Suit
• Drugmakers Fight To Undo Loestrin Antitrust Class Cert.
• Pfizer Defends Arbitration Pact's Confidentiality Language
• Judging A Book: Castillo Reviews 'Raising The Bar'
• CVS Sued Over Injury From Ear Drop, Eye Drop Mix-Up
• Medical Tech Co. Exits 'Stealth Mode' With $35M Fundraise
• A Chance To Clarify Medical Device Patent Indefiniteness
• FTC Concerns Over Bristol-Myers Deal Raise Questions
• Dissecting The Inherent Tension In Today's TCPA Landscape
• AstraZeneca Hit With Pay-For-Delay Suit Over Seroquel XR
• Allergan To Pay $2.7M To End Certain Generic-Delay Claims
• Zimmer Hit With $7.7M Hip Implant Verdict In Damages Retrial
• Salix Clears Teva's Ulcerative Colitis Drug For 2021 Launch
• Purdue Says Mass. Opioid Suit Sets Dangerous Precedent
• Pa. Justices Snub Appeal Over $2.5M Risperdal Verdict
• Online Pharmacy Says Anthem Illegally Axed It From Network
• FDA Focus: What Foley & Lardner's Practice Chair Is Watching
• Incyte Sues Incysus For Having Too Similar A Name
• EU Ready For WTO Showdown Over Turkish Drug Rules
• Mylan CEO Must Face New EpiPen Deposition, Judge Rules
• J&J Unit Wins Toss Of Suit Over Breast Implants
• How To Get The Most Out Of An Expert Witness
• Ropes & Gray Steers Vapotherm's $45M Follow-On Offering
• J&J, Colgate Cleared In Travel Agent's Talc Case
• 3rd NY Doc Cops Plea In Insys Kickbacks Case
• Fed. Circ. Design Patent Case Can Guide Medical Device Cos.
• DOJ's Bid To Toss Whistleblowers' Gilead FCA Suit Hits Snag
• J&J Expert Says Natural Causes At Fault In Woman's Cancer
• Longfellow Buys Bain Research Triangle Properties For $405M
• Sackler Case Could Blow Up High Court's 'Original' Docket
• Biopharma Co. Says Investor Suit Tries To Go Around Board
• Spencer Fane Continues Growth With 19-Atty Add In Houston
• Janssen Gets Third Co. To Put Off Invokana Generic
• FDA Limits On Vasopressin Compounding Valid, Says Judge
• Trump Ups Pressure On China With Fresh Tariff Threat
• Amgen, Teva Antitrust MDL Over Sensipar Going To Del.
• AVX Can't Shake Greatbatch's $22M Pacemaker Patent Win
• Life Sciences Firm Vida Ventures Closes $600M Fund
• Perrigo Investors Largely Beat Bid To Nix Takeover Suit
• Bankruptcy Courts' Buzzkill Of The Marijuana Industry